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Abstract: The use of combination therapies for the treatment of a range of conditions is now well
established, with the component drugs usually being delivered either as distinct medicaments or
combination products that contain physical mixes of the two active ingredients. There is, however,
a compelling argument for the development of compartmentalised systems whereby the release,
stability and incorporation environment of the different drugs may be tailored. Here we outline the
development of polymeric fine fiber systems whereby two drugs used for the treatment of wounds may
be separately incorporated. Fibers were delivered using a newly developed handheld electrospinning
device that allows treatment at the site of need. Crucially, the delivery system is portable and may be
used for the administration of drug-loaded fibers directly into the wound in situ, thereby potentially
allowing domiciliary or site-of-trauma administration. The three-layered fiber developed in this study
has polyethylene glycol as the outermost layer, serving as a structural support for the inner layers.
The inner layers comprised iodine complexed with polyvinylpyrrolidone (PVP) and metronidazole
dispersed in polycaprolactone (PCL) as a slow release core. The systems were characterized in terms
of structure and architecture using scanning electron microscopy, transmission electron microscopy,
attenuated total reflection Fourier transform infrared spectroscopy and diffractometry. As antibacterial
creams are still used for managing infected wounds, the performance of our trilayered fiber was
studied in comparison with creams containing similar active drugs. Drug release was measured
by UV analysis, while antimicrobial efficiency was measured using agar diffusion and suspension
methods. It was found that the trilayered systems, averaging 3.16 µm in diameter, released more drug
over the study period and were confirmed by the microbacterial studies to be more effective against
P. aeruginosa, a bacterium commonly implicated in infected wounds. Overall, the portable system
has been shown to be capable of not only incorporating the two drugs in distinct layers but also of
delivering adequate amounts of drugs for a more effective antibacterial activity. The portability of
the device and its ability to generate distinct layers of multiple active ingredients make it promising
for further development for wound healing applications in terms of both practical applicability and
antimicrobial efficacy.
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1. Introduction
Chronic wounds remain a significant burden on the patient population and healthcare systems
worldwide [1], with infection being the likeliest cause of delay in healing. Moreover, the formation of
biofilms from the secretions of infecting bacteria, into which they become embedded, further inhibits healing.
Indeed, biofilms are a significant factor in 70% of wounds that remain chronic [2]. One treatment approach
is the application of antiseptics and antibiotics, preferably in combination, in order to simultaneously
suppress biofilm formation [3] and prevent infection [4]. Administering more than one drug concurrently
facilitates combinatorial selectivity, in which the different drugs involved can simultaneously inhibit
several associated facets of a disease process. In addition, localisation allows for the efficient targeting of
tissues, thereby maximising drug efficacy while also minimising toxicity via the control of the selectivity
of the region of the body exposed to the therapeutic agent [5]. There is a need for wound management
strategies that utilise a multifaceted approach to simultaneously target pathogeneses of the wound.
For instance, diabetic foot ulcers (DFUs) are among the most difficult wounds to clinically manage, and it
has long been established that anaerobes are typically associated with deeper and more severe infections
in these kinds of ulcers [6]. Furthermore, as it is common to isolate several microbial species from infected
wounds such as DFUs [7], an approach utilising combination therapies where multiple active agents are
efficiently delivered simultaneously will be required for treating such wounds.
Combination therapies are nevertheless hampered by a lack of compartmentalisation between
the associated drugs. Current clinical practice in wound care, for instance, involves the application of
multiple and distinct delivery systems that lead to the variability of dose and poor control of local
concentrations. A more elegant solution would be to deliver a compartmentalised system whereby,
irrespective of the different physicochemical properties of the drugs, the possibility exists for tuning
the release while also enhancing the stability and localisation of the different agents to maximise
therapeutic benefits. Indeed, multi-compartmentalisation is regarded as a potentially crucial strategy
for delivery as it offers the potential for the efficient delivery of diverse forms of active entities [8].
Our suggested method utilises an on-demand/need approach in which layered fibers are applied
to wounds at the point of need, with each distinct layer containing a different therapeutic agent or a
functionalised controlling layer. The middle layer has iodine stabilised in polyvinylpyrrolidone and
intended as an antiseptic to sanitise the wound area, paving the way for a more effective anti-bacterial
action from metronidazole contained in slowly degrading polycaprolactone making up the core
of this unique fiber system. Iodine, in previous studies, has been shown to effectively inhibit the
formation and growth of biofilms [3], thus informing our decision to combine it with metronidazole
for a multi-targeted approach to wound management. The compartmental encapsulation of drugs in
distinct layers of polymeric fibrous systems has several potential advantages. Specifically, the fibrous
mesh has a high surface area and allows fluid permeation, while the layered structure within the fibers
allows the separation of drugs into physically distinct environments with the potential for tunable
controlled release. In addition, the physical flexibility and versatility of the macroscopic mesh structure
allow lesions of irregular shapes to be filled neatly [9,10].
These potential advantages of combination therapies have led to a significant increase in research
into compartmentalised structures as patient-specific drug delivery systems [11,12]. However, several
limitations hamper their practical applicability in a clinical setting. Despite recent advances in production
technologies such as multi-layer electrospinning and significant improvements in scale-up, the production
of multi-layered drug-loaded fibers requires a skilled worker operating expensive, bulky and essentially
immobile bench-top apparatus in a specialised laboratory or factory environment. Furthermore, the highly
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delicate nature of the fibers produced renders it difficult to preserve structural integrity during packaging,
transport and administration from the point of manufacture to the point of use.
It is therefore therapeutically highly advantageous to develop a portable and inexpensive device
that may produce multi-layered therapeutic materials in situ at the point of trauma. While the design
of a portable electrospinning device has been reported by several research groups [13–15], none of these
is capable of producing multi-layered structures that can be useful for developing multi-compartment
systems for the efficient simultaneous delivery of different drugs. Here, we describe a simple-to-operate,
miniaturised portable device for generating trilayered fine structures at the point-of-use. As a
proof-of-concept to explore the use of a trilayered fibrous system, we develop a new, improved
combination therapy consisting of iodine and metronidazole (MTZ) for wound dressing applications.
We demonstrate the potential clinical efficacy of this approach using drug release and antimicrobial
studies; more specifically, metronidazole (MTZ) is an antibiotic agent widely recognised as a standard
for the elimination of anaerobic bacteria [3]. Moreover, formulations combining the antibacterial
MTZ with the antiseptic iodine have been found to exhibit promising synergistic wound healing
properties [16]. The MTZ-iodine formulations are typically presented as ointments in which the drugs
are simply mixed as physical combinations [17]. Here, we load the active ingredients into different
polymeric compartments in a trilayered fiber using the portable device. More specifically, MTZ
dispersed in a biodegradable polymer, polycaprolactone (PCL), makes up the innermost core of the
trilayered fiber. The middle layer contains iodine stabilised in polyvinylpyrrolidone (PVP), the former
acting as an antimicrobial agent to rapidly sanitise the wound upon application. Finally, the outermost
layer is made of a polyethylene glycol (PEG) polymer as the shell fabric, acting to provide physical
robustness and moisture regulation as well as a wound barrier to prevent contamination.
The potential advantages of the new approach are manifold. First, by keeping each ingredient in
a separate compartment the performance and stability of the formulation are enhanced as interactions
(should they exist) between the drugs are minimised prior to the onset of action. Secondly, the core-shell
fibrous structure provides a controlled drug release while acting as an effective physical protection
and dressing for the wound. Thirdly, polymeric systems have been demonstrated to reduce irritation
and toxicity associated with antiseptics such as iodophores when used in wound care [18]. Lastly,
the portable production method allows highly specific systems to be tailored/personalised and delivered
on-site for a desired therapeutic outcome while eliminating the need for the packaging and transport
of the delicate product to the site of use, thereby further preserving the drug and dosage form integrity.
Here, we explore the manufacturing feasibility, structural architecture and potential therapeutic efficacy
of the portable trilayered system so as to establish the applicability of the approach to both the treatment
of wound infections and, more broadly, the treatment of in situ conditions under a range of settings.
2. Materials and Methods
2.1. Materials
Metronidazole (MTZ, analytical standard, Mw = 171.15 g/mol), polyvinylpyrrolidone-iodine complex
(PVP-I, European Pharmacopoeia Reference Standard with average Mw = 365 g/mol), high molecular
weight polyvinylpyrrolidone (PVP, Mw = 360,000 g/mol), polycaprolactone (PCL, Mw = 80,000 g/mol),
polyethylene glycol (PEG, BioUltra, Mw = 35,000 g/mol), dichloromethane (DCM), dimethylformamide
(DMF) and ethanol (EtOH) were purchased from Sigma Aldrich (Poole, Dorset, UK) and used as received.
MTZ and metronidazole-iodine (MTZ-I) in aqueous cream BP (British Pharmacopoeia) base were
prepared as follows: 10 g of the MTZ cream comprised of 0.1 g of MTZ (batch number MKBZ3056V,
Sigma Aldrich), 3 g of emulsifying ointment (batch number NR 10043, Pinewood Healthcare, Dublin,
Ireland), 0.1 g of phenoxyethanol (batch number STBD 3014V, Sigma Aldrich) and made up to the
target weight with purified water. The MTZ-I cream contained the same ingredients as the MTZ
cream with the addition of 0.5 g PVP-I, amounting to 0.5% elemental Iodine (equivalent to a 2:1 MTZ:
PVP-I weight ratio). Lysogeny broth (LB) and LIVE/DEADTM BacLightTM Bacterial Viability and
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Counting Kits were purchased from Thermo Fisher Scientific (Waltham, MA, USA), whilst LB agar
was purchased from Sigma Aldrich.
2.2. Solution Preparation and Characterization
To prepare the trilayered electrospun fibers, different polymer or polymer/drug solutions
were prepared, selecting materials known to enable optimised encapsulation and stable trilayered
electrospinning as well as to fulfil the objective of developing a system which combined MTZ and
Iodine for a synergistic antimicrobial outcome. Materials and parameters used in developing this
system are shown in Table 1.
Table 1. Solution composition and corresponding flow rates used in the various sections of our multiple
concentric needle systems for trilayered electrospinning.
Fiber Layer Flow Rate (mL h−1) Material Solvent
Core layer 2 4 wt % MTZ + 12 wt % PCL 4:1 v/v DCM: DMF
Middle layer 4 10 wt % PVP-I or 10 wt %PVP-I/PVP (1:1 w/w) EtOH
Shell layer 7 25 wt % PEG DCM
The physical properties of the three solutions used for the three layers of the fibers were characterised.
The surface tension was measured with a Kruss Tensiometer K9 (Hamburg, Germany) using the standard
Wilhelmy’s plate method. The electrical conductivity was measured using a conductivity meter (Jenway
3540, Bibby Scientific, Stone, Staffordshire, UK). The viscosity was measured with a digital rotational
viscometer (Brookfield DV-111, Harlow, Essex, UK) using spindle number 18 at a shear stress of 3.5 Pa.
All procedures were repeated five times, and the mean value of the readings were recorded. The viscometer
was calibrated automatically by following prompts to run a complete cycle without the spindle in place.
The tensiometer was calibrated by taking the surface tension of distilled water at room temperature and
comparing it with the literature value. The conductivity meter was calibrated by immersing the probe in
the conductivity standard (Bibby Scientific, Staffordshire, UK), and the meter was adjusted until a reading
of 1194 µS cm−1 at 22 ◦C was obtained.
2.3. Portable Trilayered Electrohydrodynamic Apparatus and Processing Conditions
The portable trilayered electrohydrodynamic apparatus is shown in Figure 1. Additional photographs
and a schematic diagram is shown in the Supplementary Information (Section S1, Figure S1). The three
different solutions were each loaded in a 10 mL syringe attached to a stainless-steel concentric needle
system with multiple inlets and outlets. The concentric needle system is an additive system that can be
changed between single-layer, two-layer, trilayer and quad-layer depending on the number of layers
required for the products; in this work, the system is used in the trilayer mode. Fibers were generated using
the positive polarity of the voltage supply and collected on a grounded aluminum plate. Three miniature
high-precision micro-syringe pumps (Micrel mph+, Inspiration Healthcare Limited, UK) were used, each
supplying one of the three solutions through the concentric needle system, charged by a miniature high
voltage supply able to generate up to 33 kV at 10 W (EMCO 4330+, XP Power, UK). The solutions were
electrospun at a positive voltage of 17 kV, a working distance (between the needle exit and the collector) of
15 cm, and flow rates of 2, 4 and 7 mL h−1 for the core, middle and shell solutions, respectively (Table 1).
All electrospinning procedures were carried out under an ambient temperature, humidity and pressure
(22 ◦C, 1 atmospheric pressure, 40–50% relative humidity), as described in our previous work [19].
2.4. Fiber Characterisation
The surface morphology and diameter of the fibers were studied using a Quanta 200F field emission
scanning electron microscope (Thermo Fisher Scientific). Prior to observation, each sample was coated
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with gold using a Quorum Q150T turbo-pumped sputter coater (Quorum Technologies, Lewes, East
Sussex, UK) for 90 s. The average fiber diameter was determined using Image-Pro Plus software (Media
Cybernetics, Inc., Rockville, MD, USA) and was based on at least 100 measurements from the scanning
electron microscope (SEM) images. In order to confirm that the fibers had three distinct layers, transmission
electron microscope (TEM) imaging of fibers collected on carbon-coated grids was conducted using TEM
CM 120 Biotwin (Thermo Fisher Scientific), operating at an accelerating voltage of 100 kV.
To verify the composition of the fibers, attenuated total reflection Fourier transform infrared
spectroscopy (ATR–FTIR) was carried out using a Vertex 90 spectrometer (Bruker, Coventry, West
Midlands, UK). The measurements were interpreted using OPUS Viewer version 6.5 software. Each
sample was scanned 32 times at a resolution of 2 cm−1. To investigate the solid-state of the drugs
entrapped in the multi-layered fibers, samples were analysed using a D/Max-BR diffractometer (RigaKu,
Tokyo, Japan) with Cu Kα radiation. Analyses were conducted at 40 mV and 30 mA over the 2θ range
of 5◦–80◦ at a rate of 2◦ min−1. The data obtained were converted to diffractograms and evaluated
using OriginPro 7.0 software (OriginLab Corporation, Northampton, MA, USA).
2.5. Drug Release Study
To measure and compare the amount of drug released respectively from the fiber and cream formulations,
we used a system utilising a dialysis membrane as a means of filtration to minimise the extent of other
materials from either the trilayered fibers or creams interfering with the amount of MTZ sampled for the UV
analysis. 50 mg of the drug-loaded sample was first enclosed in a 5 mL dialysis membrane with a molecular
weight cut-off of 8000 g mol−1. The sample was then immersed in a 45 mL vessel (sampling chamber).
A physiological temperature of 37 ◦C and a continuous agitation at 80 rpm were maintained throughout the
release study using a benchtop incubation shaker (Sciquip, Newtown, Shropshire, UK). The total duration
of the study was five days. Samples of 3 mL were taken at various intervals from the vessel. A 3 mL blank
medium was added after each sampling to maintain a constant total volume.
An ultraviolet-visible (UV–Vis) spectroscopy (Jenway 6305 UV/Visible spectrophotometer, Bibby
Scientific, Stone Staffordshire, UK) operating at 322 nm was used to quantify the amount of drug
present as a function of time. To determine the total amount of drug entrapped during fiber formation,
1 mg of the MTZ-loaded trilayered fibers was dissolved completely in 10 mL of dichloromethane,
followed by measuring the solution’s absorbance.
2.6. Antimicrobial Activity
Two microbial inhibition assays were carried out to compare the antimicrobial activity of the
prepared trilayered fibers and MTZ-I/MTZ cream formulations. The first assay assessed the area
of inhibition on an agar plate, while the second assay assessed the 24-h bactericidal results in cell
suspensions analysed by flow cytometry. Pseudomonas aeruginosa NCTC 12903 (Public Health England)
was chosen as the model microorganism to assess the antibacterial properties of the prepared trilayered
fibers and MTZ-I/MTZ cream formulations. P. aeruginosa is one of the most common bacteria isolated
from chronic wounds, typically resident in the deepest region of the wound bed [20]. Furthermore,
P. aeruginosa is well known for its high virulence, causing severe morbidity by releasing proteases
and cytotoxic substances in chronic wound environments and thereby seriously impeding wound
healing [21]. P. aeruginosa NCTC 12903 is isolated from blood cultures and is commonly used for
susceptibility testing. P. aeruginosa NCTC 12903 was propagated as per the manufacturer’s instructions
and stored at −80 ◦C in a MicrobackTM.
2.6.1. Agar Diffusion Assay
A single colony of P. aeruginosa NCTC 12903 was suspended in 100 µL of sterile deionised water
and transferred to an LB agar plate. A plastic L-shaped spreader was used to spread the bacteria over
the plate. The plate was allowed to air dry. 1 g of the fibers and cream were placed in the centre of the
plate and had an area coating of approximately 1 cm in diameter (concentration of 10 wt %). After
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application, it was ensured that the fibers had made complete contact with the agar surface. The plates
were incubated for 24 h at 37 ◦C. The assay was performed in triplicate for each treatment method.
The antibacterial activity was assessed by the diameter of the growth inhibition zone. Photographs of
agar plates and inhibition zones are shown in the Supplementary Information (Section S3, Figure S3).
2.6.2. Suspension Assay
A method previously used for assessing antimicrobial activity [22] was adapted for this study.
A single colony of P. aeruginosa was suspended in 30 mL of sterile LB broth. The suspension was incubated
at 37 ◦C and 150 rpm until it reached its mid-exponential phase (OD600 0.4, equivalent to 8 Log10
CFU/mL). A 1:100 dilution of the bacterial suspension was inoculated into sterile LB broth. The fibers and
cream were respectively added to the bacterial suspensions at 10 wt % and incubated for 24 h at 37 ◦C and
150 rpm. Flow cytometry was used in conjunction with the LIVE/DEAD BacLight Bacterial Viability assay
to enumerate the number of live and dead cells in the suspension post-incubation. This method relies on
the use of fluorescent stains, SYTO® 9 and propidium iodide (PI) (both from Thermo Fisher Scientific).
SYTO® 9 is a green fluorescent nucleic dye which is able to penetrate both live and dead cells, whilst PI is
a red fluorescent intercalating stain which can only penetrate cells with damaged membranes (non-viable
cells) to displace the SYTO®9 and which results in a red colouration. A stock solution of PI and SYTO® 9
was prepared according to the manufacturer’s instructions. 180 µL of the stock staining solution was
added to 20 µL of diluted sample and incubated at room temperature in the dark for 15 min.
After incubation, cells were acquired using a calibrated Guava easyCyte® flow cytometer and
InCyte software (guavaSoft 3.1.1) (Luminex Corporation, Austin, TX, USA). Gates were set up
using positive (media and bacteria only), negative (media only) and fluorescent minus one control
(single-stained positive controls). 50,000 events were collected, and the bacteria acquisition gates were
determined using forward scatter and side scatter channels to eliminate background noise and debris
from the sample. The gated population of bacteria was then analysed using fluorescent channels.
FlowJo was used to gate the live and dead bacterial cell counts, where the proportions of live and dead
bacteria cells were calculated. All experiments were repeated at least three times.
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Figure 1. Above: Photograph showing a size comparison between the old conventional large, bench-top
setup and the new three-compartment portable electrohydrodynamic device held by a researcher.
Below: A photograph of the multiple needle system used to generate three-layered fibers and the high
voltage source and precision pu p used in developing the device.
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3. Results
3.1. Portable Multi-Layer Electrospinning Device
The core-shell concentric electrospinning device could be a useful innovation in and of itself, in that
this portable assembly can be readily adapted to generate single-layer, core-shell layer, three-layer and
four-layer products, depending on the number of compartments required. The components for the
portable multi-layer electrospinning device are off-the-shelf and simple to assemble; the assembly of
the miniature high voltage (HV) supply and precision syringe micro-pumps are less expensive but as
effective as their heavy, voluminous and practically immobile bench-top counterparts. The portable
HV supply (adapted from EMCO 4330+, XP Power) can produce 0–33 kV at 10 W, a wider range than a
bench-top HV supply which typically supplies 0–30 kV. The mini HV unit weighs less than 0.7 kg at a
volume of 0.28 m3, and costs < £800. This is 95 times smaller, 10 times lighter and 3 times cheaper than
a traditional HV unit (~7 kg, 27 m3, £2–5k).
The high precision micro-pumps (Micrel MP mlh+, Micrel Medical Devices SA, Koropi, Athens,
Greece) are compact, lightweight and affordable (each at 0.15 m3 (volume), 0.2 kg (weight), when inclusive
of 6 AAA batteries, and retailing at £1k). The battery-operation can sustain up to 600 h of continuous
infusion at a high precision of 0.1 mL h−1. These micro-pumps are as effective as conventional syringe
pumps for electrospinning but are at least 50 times smaller, 10 times lighter and 4 times cheaper (e.g.,
conventional precision syringe pumps are ~7.5 m3, 2 kg and retail at £2–4k). The apparatus is easy to
operate and can be hand-held for the direct generation of structures (both particles and fibers) at the
point-of-use (Figure 1). Previously, we demonstrated how this miniaturised device could be used in the
manufacture of a system containing silver nanoparticles as antibacterial agents to be applied as a wound
dressing [17]. This study represents, however, the first time trilayered electrospinning has been achieved
using a truly miniaturised setup.
3.2. Solution Compositions for Optimal Trilayered Fiber Formation
To generate trilayered fibers with distinct compartments containing MTZ and iodine under
optimal processing conditions, we first characterised the physical properties of each solution used
for the trilayered co-flow (Table 2). Trilayered fibers generated from 10 wt % of PVP-I solutions were
found to be beaded, with an average diameter of 1.08 ± 0.54 µm (Figure 2a,c). The bead-on-string
morphology is undesirable because it compromises the compartmental integrity of the trilayered
fibers. It is well known that increasing the solution viscosity leads to a reduction in the undesirable
bead-on-string morphology [23]; the viscosity of 10 wt % of PVP-I solutions at 4.1 ± 0.3 mPa·s was
too low to enable a sufficient molecular chain entanglement for bead-free fiber formation (Table 2).
By mixing the PVP-I complex with a high molecular weight PVP (Mw at 360,000 g/mol, Table 1),
the resultant PVP-I/PVP solution had a higher viscosity of 78.6 ± 1.2 mPa·s and enabled bead-free
fiber formation (Table 2, Figure 2b). The smooth trilayered fibers had an average diameter of 3.16
± 1.05 µm (Figure 2d). The increased fiber diameter is attributed to both the increased viscosity as
well as the lower electrical conductivity of the PVP-I/PVP solution in comparison to the pure PVP-I
solution used in forming the beaded fibers [24]. The electrical conductivity of the pure PVP-I solution
was 340 ± 4 µS m−1, which is nearly threefold higher than that of the PVP-I/PVP solutions at 121 ±
0.5 µS m−1. A decrease in solution electrical conductivity is known to generate larger fiber diameters
in electrospinning [25]; hence, these results are compatible with the existing knowledge base.
The bead-free, smooth continuous fibers comprising PCL + MTZ, PVP-I/PVP (1:1) and PEG,
henceforth referred to as trilayered fibers, were used for the subsequent analysis in this study.
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3.3. Analyses of the Trilayered Fiber Compositions 
3.3.1. Structural Features 
TEM and SEM analyses were performed to confirm the multi-layered structure (Figure 3). The 
three distinct layers were clearly observed under TEM (Figure 3a), confirming the three-layer core-
shell structure of the fibers. As shown in the TEM image, the core layer corresponds to the MTZ-PCL 
centre, the middle layer corresponds to the PVP-I complex, and the outermost layer corresponds to 
the PEG shell of the fiber. While an examination of the fibers by SEM can typically only reveal the 
surface morphology (Figure 3b), the images shown in Figure 3c–e nevertheless allow the three layers 
to be visualised for those fibers that demonstrate differential extensions of the layers. 
 
Figure 2. (a,b) SEM images of the fibers, and (c,d) the corresponding fiber diameter distribution profiles.
Left panel: beaded trilayered fibers, generated with 10 t % PVP-I in the middle layer. Right panel:
smooth trilayered fibers, generated with 10 wt % PVP-I/PVP (1:1 w/w) in the middle layer.
3.3. Analyses of the Trilayered Fiber Compositions
3.3.1. Structural Features
TEM and SEM anal ses were performed to confirm the multi-layered structure (Figure 3). The three
distinct layers were clearly observed under TEM (Figure 3a), confirming the three-layer core-shell
structure of the fibers. As shown in the TEM image, the core layer corresponds to the MTZ-PCL centre,
the middle layer corresponds to the PVP-I complex, and the outermost layer corresponds to the PEG
shell of the fiber. While an examination of the fibers by SEM can typically only reveal the surface
morphology (Figure 3b), the images shown in Figure 3c–e nevertheless allow the three layers to be
visualised for those fibers that demonstrate differential extensions of the layers.
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and PVP-I, to confirm the entrapment of the active ingredients i the fibers (Figure 4). Free iodine
interacts with the negative end of the C=O dipole of PVP molecules, forming a co plex with the amide
functional group a d is identified as a characteristic peak around 1654 cm−1 [26,27]. This characteristic
pe k was seen in the PVP-I spectrum as well as the fibers, confirming the presence of iodine. Peaks
occurring at 1479, 1275, 1070 and 870 cm−1 representing the N=O, C–O, C–N and C–NO2 stretching
are characteristic of MTZ [28,29]. These characteristic p aks were obs rved in both the pure MTZ
compound and the generated fib rs, confirmi g the entrapment of MTZ in the fibers.
Understanding the solid-state of the active ingredients in the drug-carrying fibers, whether it
be amorphous, crystalline or a mixture of both, can help inform the likely performance and storage
behaviour of such formulations [30]. The XRD spectra of the fibers were compared to those of the
individual active ingredients to determine the crystalline state of the drug-loaded fibers. The differences
between the spectra reflect the extent of change that the solid-state of the starting material has undergone
post-processing. Figure 5 shows that PCL, MTZ and PEG are in their crystalline state (Figure 5a–c),
while the PVP-I is largely amorphous (Figure 5d).
The drug-loaded fibers containing the aforementioned materials were found to be part-crystalline
and part-amorphous (Figure 5e), almost certainly reflecting the crystalline components of the polymers
(PCL and PEG). However, the extent of crystallinity of the polymers in such a complex architecture
is difficult to ascertain, given the known propensity of electrospinning to elicit polymer chain
reorganisation during electrospinning [31]. While the presence of crystalline MTZ as a minor
component cannot be completely precluded on the basis of this data, the absence of any evidence for
major MTZ peaks at angles where the polymer response was low (and hence unlikely to hide the drug
response) would support drug amorphisation. MTZ is sparingly soluble in aqueous systems, and
hence molecular dispersion in the fiber would promote dissolution via the absence of a crystal lattice,
in turn potentially aiding bioavailability.
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trilayered fiber samples are largely amorphous.
3.4. Drug Release Study
MTZ is topically administered via creams, gels or lotions in strengths typically ranging between
0.75 and 1 wt % [15]. With this as a guide, the concentrati s and flow rates of the core-middle-shell
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solutions during trilayered electrospinning were optimised (Table 1) to enable a final encapsulation
concentration of 1 wt % MTZ within the total volume of the core-shell fiber.
Drug release from the trilayered fibers was compared to those from creams containing similar
quantities of MTZ. Antibiotic creams are currently routinely applied as part of wound dressings,
with the hope of releasing the active drug contained therein over the period during which the wound
dressing is in place, usually over several days [32–34]. While the intended purpose of the fibers
(treatment of wound infection and promotion of healing via tailored release of active drug, moisture
control and provision of a physical barrier to prevent further contamination all in one) is distinct
from that of antibacterial creams for wounds, there is merit in comparing the new formulation to an
existing and established delivery system, particularly in terms of looking at the longer-term supply of
adequate amounts of active drugs than would typically be required from a cream. The drug release
study from the fibrous formulation and two cream formulations (MTZ with and without iodine) is
shown in Figure 6. To compare the release of drug from the trilayered fibers and creams, a setup
comprising the delivery system enclosed within a dialysis membrane in a volume of 5 mL and further
immersed in a liquid with a volume of 45 mL (outer chamber) was used, from which sampling was
made from the outer chamber to determine the amount of drug released. This was to ensure that
the delivery systems being studied were totally immersed within the dissolution media, as both
systems had tendencies to float and disrupt the continuous release of the drug into the media. In this
two-chamber setup, sampling for analysing the drug release was possible from the outer chamber,
but as the drug was released into the inner chamber enclosed by a dialysis membrane it was necessary
to establish the relationship between the sampled drug and the actual amount of drug released into
the dialysis chamber. For a more robust comparison between the drug released from creams and
the trilayered fibers, it was necessary to establish that, regardless of the difference in the diffusion
coefficient (which is certain to be the case for creams and fibers), the amount of drug sampled from the
outer chamber for analysis maintains its relationship with the actual amount of drug released within
the dialysis membrane.
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To dete mine this relationship, som assumption and the modelling of the experimental data from
the study were made. These were essential to establish an accurate comparison of drug release from
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the trilayered fibers and creams. The mathematical modelling of the experimental data is presented as
Supplementary Information (Section S2, Figure S2).
3.5. Release from the Trilayered Fiber System and Creams
As it has been established (in the Supplementary Information, Section S1) that the sampled
drug profiles reflect the profiles of the actual drug released, regardless of the system being assessed,
the amounts of drug sampled from the fiber and cream systems were compared. From the fiber system,
97.8 ± 2.3% of MTZ had been released after five days. In contrast, only 48.5 ± 2.2% and 49.5 ± 2.7%
had been released from the MTZ and MTZ-iodine cream formulations, although all systems being
compared were formulated to contain the same amount of MTZ. In addition, the inclusion of iodine in
the cream formulations was not found to influence the MTZ release significantly. It has been reported
for creams that only the fraction of the MTZ present in the external aqueous phase would be able to
diffuse out for therapeutic activity [35,36]. On the other hand, MTZ as a solid dispersion in a polymer
matrix in the trilayered fiber is most likely released via drug diffusion and matrix erosion [37], a process
significantly facilitated by the increased surface area to volume ratio acquired by the compartmental,
fiber delivery format. Suboptimal concentrations of antibiotics at topical infection sites have been
confirmed to confer a survival advantage of bacteria leading to antimicrobial resistance and ultimately
clinical failures [38]. Having a solid dispersion of MTZ in a polymeric matrix ensured the release of
more antibiotics from the fibers, as seen in the release study, and this was confirmed to offer better
antibacterial action against the test organisms used in our antimicrobial assay, discussed in Section 3.5.
The examination of the first 8 h of release indicated that 69.9 ± 2.3% of MTZ in the compartmentalised
fiber system had been released compared to 37.3 ± 3.2% and 35.7 ± 2.8% of the MTZ-I and MTZ
cream formulations, respectively. Thus, the three-layered fiber system, unlike the cream formulations,
appears to deliver more of the active ingredient within the specified time.
3.6. Antimicrobial Assays
P. aeruginosa, a common Gram-negative rod-shaped bacterium known for its resistance to
antimicrobials [39], was selected as the test microorganism to assess the antibacterial activity of MTZ-loaded
fibers compared with MTZ and MTZ-I creams. Furthermore, biofilms secreted by P. aeruginosa are
commonly associated with difficult-to-heal chronic wounds [40], and hence this organism provides a
highly relevant model for the novel fiber delivery system. Previous research has shown MTZ to be an
effective antibiotic against resistant strains of P. aeruginosa when used in combination therapies [41].
Two antimicrobial assays were employed: (1) an agar diffusion assay to investigate the performance
on a surface, thereby mimicking topical delivery (Supplementary Information, Section S3.1, Figure S3),
and (2) a bacterial cell suspension approach to investigate the antimicrobial performance of the fibers
when immersed in liquid media, hence mimicking anaerobic conditions.
Flow cytometry was used to give a rapid, comprehensive and quantifiable overview of the
bacterial population post-treatment (Supplementary Information, Section S3.2, Figures S4 and S5).
Previous literature has shown flow cytometry to provide a more accurate quantitative measurement of
cell viability when compared to plate count estimates [22].
In both assays, the trilayered fibrous formulation demonstrated a more potent elimination of
P. aeruginosa cells than the MTZ and MTZ-I creams did. The antimicrobial effect was due to the
presence of MTZ, as the drug-free fiber controls showed no antimicrobial action while the formulations
containing iodine in addition to MTZ did not result in significantly higher cell death rates (Figure 7).
More specifically, in the agar diffusion assay, the trilayered fibers inhibited a circular area with an
average diameter of 35 ± 1.4 mm, whereas the MTZ and MTZ-I formulations resulted in growth
inhibition zones with average diameters of 25 ± 1 mm and 25 ± 2 mm, respectively (Figure 7a shows
the corresponding zone areas).
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cell death rate found in samples with the fibers is attributed to the better release of MTZ from the 
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Figure 7. (a) Growth inhibition zone area of P. aeruginosa following 24-h incubation on LB agar
plates with various drug formulations. (b) Dead/live cell count by flow cytometry of cell suspensions
incubated for 24 h with drug-loaded fiber and crea sa ples.
Ad itional y, a 74% cel death as note ft r fi er sa ples in
suspension, whereas a rate of 37 an ll t , ti l , t ft r ex osure to TZ
and MTZ-I cream formulations over the sa e peri f i ti ( i r ). e ore significant
cell death rate found in samples ith t e fi ers is attri te t t e etter release f Z fro the
trilayered compartmental syste , hich is also confir e by the r g release study in Section 3.4.
The enhanced release from the fiber syste enabled a better availability and stronger bactericidal
action, compared to the creams containing similar quantities of MTZ. The multi-layered fiber structure
allowed the release of MTZ and iodine from different compartments and facilitated the antibacterial
actions of the active ingredient. The inherent properties, mainly a high surface-to-volume ratio and
surface porosity of fibers, expedited the release of active ingredient for antibacterial activity, whereas
the limited activity in the cream formulations are attributed to the fact that the non-compartmental
system only makes a small fraction of the active ingredients available for antibacterial action.
4. Discussion
Re-engineering an electrospinning device to be more accessible and practically useful for delivering
multiple active ingredients simultaneously is an intervention with a tremendous potential for improving
the management of difficult chronic wounds. One such challenging clinical condition that stands
to benefit from such an innovation is diabetic foot ulcers (DFU), given the need to deliver multiple
active agents to simultaneously target the various underlying causes of such wounds. Presently,
the gold standard for treating difficult infected chronic wounds where vascularisation is impaired
includes debridement, treating the infections, the application of growth factors and modulators,
revascularisation and off-loading the ulcer [42]. In treating infections and applying other interventions
such as growth factors, agents are typically applied separately, and wound dressings capable of
delivering multiple agents simultaneously are yet to be used. Electrospinning systems that could
potentially deliver such interventions are currently in preparatory stages [43].
Therefore, developing a multi-layered system that clearly isolates active ingredients from each
other until required for activity shows tremendous potential for improving the healing process of such
difficult-to-heal wounds. Having demonstrated that our portable multi-compartment fiber generating
system is capable of releasing more antibiotics in comparison to creams for a superior antibacterial
activity points to the possibility of further developing this portable electrospinning device into an
efficient and cost-effective means of managing difficult wounds in the near future.
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5. Conclusions
In summary, this work presents three novel findings: (1) the point-of-need generation of trilayered
fibers containing compartmentalised drugs for in situ wound treatment; (2) a simple-to-operate, miniaturised
portable device for the electrospinning of multi-layered core-shell structures at the point-of-use; (3) the
delivery of multiple active drugs for a possible combination therapy using a core-shell fiber configuration.
The drug-loaded fibers were characterised by scanning electron microscopy, transmission electron microscopy,
attenuated total reflection Fourier transform infrared spectroscopy and X-ray diffraction. In addition,
the trilayered fibers demonstrated a superior antibacterial activity in comparison with the non-compartmental
cream systems. This work paves the way for applying multiple therapeutic agents simultaneously in a
compartmental format at the point-of-need and strengthens the prospects of having more efficient and
cost-effective means of managing difficult wounds in the foreseeable future.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/4/373/s1.
Figure S1: (a) Assembling various components of the portable electrospinning device; (b) the device in operation,
producing yellowish metronidazole/iodine loaded fibers; and (c) a schematic representation of the device setup.
Figure S2. (a) Fractional release from the delivery systems (blue) and into the outer liquid (orange) as a function
of time for scenarios with varying diffusion coefficients from the delivery system (Dp) and through the dialysis
membrane (Dm). (b) Cumulative percentage of drug released from the trilayered fibersystems and cream
formulations obtained during the study over a five-day period. Figure S3. Photographs of the results showing
the growth inhibition of P. aeruginosa following the 24-h incubation of the bacterial cells on LB agar plates with:
(a) MTZ cream, (b) MTZ-I cream, and (c) triaxial fibers. Figure S4. A schematic representation of cell sorting using
flow cytometry [Image source: Sari Sabban©2011 / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)].
Figure S5. Dead/live cell count by flow cytometry of cell suspensions incubated for 24 h for (a) control (without
cream or fiber) 4% dead/96% live, (b) plain fibers without drug 3% dead/97% live, (c) drug-loaded cream 59%
dead/41% live and (d) drug-loaded fiber 76% dead/24% live.
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